22Nov2009
Filed under: Uncategorized
Author: mediabot
Circassia Ltd, a specialty biopharmaceutical company focused on allergy, announced positive results from a recently completed phase II clinical study of its ToleroMune(R) cat allergy therapy, which successfully identified the optimal dosing regimens to progress into late-stage development.



Circassia Announces Successful Results From Phase II Clinical Study Of ToleroMune(R) Cat Allergy Therapy
Related posts:
- Successful Phase III Clinical Trial Results Reported For NovoCure’s Novel Medical Device For Treatment Of Recurrent Glioblastoma Data from the first phase III clinical trial of NovoCure’s NovoTTF device for treatment of patients with recurrent glioblastoma (GBM) were presented as a late breaking abstract during the Neuro-Oncology...
- Acrux Announces Successful AXIRON™ Phase III Trial Results Acrux Announces Successful AXIRON™ Phase III Trial Results Australian company, Acrux, announced positive results from a Phase III trial evaluating the safety and efficacy of AXIRON™ in 155 men with...
- Alkermes Announces Initiation Of Phase 1 Clinical Study Of ALKS 37 For The Treatment Of Opioid-Induced Constipation Alkermes, Inc. (NASDAQ: ALKS) announced the initiation of a phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the opioid agonist effects...